Synagis Market Report 2026

Synagis Market Overview

• The Synagis market growth in the historic period has been driven by increasing incidence of rsv infections in infants, growing awareness of preventive monoclonal therapies • Market expansion is supported by rising investments in next-generation rsv prevention therapies, increasing focus on long-acting monoclonal antibodies • Growth Driver: Rising Prevalence Of Chronic Respiratory Conditions Driving The Market Growth • Market Trend: First-Line Defense Against Respiratory Syncytial Virus (RSV) Now Accessible For High-Risk Infants • North America was the largest region in 2025 and Europe is the fastest growing region.

What Is Covered Under Synagis Market?

Synagis (palivizumab) is a medication used to prevent serious lower respiratory tract infections caused by the respiratory syncytial virus (RSV) in high-risk infants and children. It is a monoclonal antibody that works by binding to the RSV virus, preventing it from entering and infecting cells in the respiratory system. The main types of clinical indications for synagis are respiratory syncytial virus (RSV) prophylaxis, premature infants with bronchopulmonary dysplasia (BPD), congenital heart disease (CHD), and immunocompromised infants and children. Respiratory syncytial virus (RSV) prophylaxis involves preventive approaches, such as administering monoclonal antibodies like synagis, to lower the risk of RSV infections, especially in infants and young children at high risk. It is formulated in several ways, such as 50 milligrams (mg)/0.5 milliliters (ml) and 100 milligrams (mg)/1 milliliters (ml), and distributed through various distribution channels, including wholesale distributors and online retailers. It is used by several end users, such as pediatric and adults.

What Is The Synagis Market Growth Forecast?

The growth in the forecast period can be attributed to rising investments in next-generation rsv prevention therapies, increasing focus on long-acting monoclonal antibodies, expansion of biologic manufacturing capacity, growing pediatric healthcare expenditure, increasing adoption of precision immunotherapy approaches. Major trends in the forecast period include increasing adoption of monoclonal antibody-based rsv prophylaxis, rising focus on preventive pediatric immunotherapies, expansion of cold-chain dependent biologic distribution, growing emphasis on high-risk infant protection, improved manufacturing scalability for biologics.

Global Synagis Market Segmentation

1) By Clinical Indication: Respiratory Syncytial Virus (RSV) Prophylaxis, Premature Infants With Bronchopulmonary Dysplasia (BPD), Congenital Heart Disease (CHD), Immunocompromised Infants And Children 2) By Formulation: 50 Milligrams (mg)/0.5 Milliliters (mL), 100 Milligrams (mg)/1 Milliliters (mL) 3) By Distribution Channel: Wholesale Distributors, Online Retailers 4) By End-User: Pediatric, Adults

What Are The Drivers Of The Synagis Market?

The increasing prevalence of chronic respiratory conditions is expected to propel the growth of the synagis market going forward. Chronic respiratory conditions are prolonged illnesses that impact the lungs and airways, leading to ongoing breathing problems. The prevalence of chronic respiratory conditions can be attributed to several factors, including an aging population, smoking and lifestyle choices, genetic and occupational factors, and environmental pollution. Synagis (palivizumab) prevents severe respiratory syncytial virus (RSV) infections in high-risk infants and children, reducing complications and exacerbations in those with chronic respiratory conditions. For instance, in June 2025, according to World Health Organization (WHO), a Switzerland-based specialized agency of the United Nations, reported that chronic respiratory diseases affect more than 80 million people, and many more are undiagnosed, according to a new WHO and European Respiratory Society report. Therefore, the increasing prevalence of chronic respiratory conditions is driving the growth of the synagis industry. The increase in healthcare expenditure is significantly driving the growth of the synagis market in the future. Healthcare expenditure refers to the financial resources spent on providing healthcare services, including medical treatments, hospital care, medications, and preventive measures. The increase in healthcare expenditure can be attributed to several factors, including an aging population, rising chronic diseases, public health crises, and increased demand for services. Rising healthcare expenditure is facilitating increased investment in preventive treatments for high-risk infants and young children. As healthcare budgets grow, more funding is directed toward medications such as synagis, helping to prevent severe respiratory illnesses. For instance, in May 2024, according to the Office for National Statistics, a UK-based government department, total healthcare expenditure increased by 5.6% in nominal terms between 2022 and 2023, compared with growth of 0.9% in 2022. Therefore, the increase in healthcare expenditure is driving the growth of the synagis industry.

Key Players In The Global Synagis Market

Major companies operating in the synagis market are Swedish Orphan Biovitrum AB

Global Synagis Market Trends and Insights

Major companies operating in the Synagis market are focusing on obtaining drug approvals to provide preventive therapy for respiratory syncytial virus (RSV), addressing a significant unmet medical need. Drug approval is the regulatory process in which authorities evaluate a drug’s safety, efficacy, and quality based on clinical trial data before authorizing it for use. For instance, in September 2023, AstraZeneca Pharma India Ltd., an India-based biopharmaceutical company, obtained approval from the Central Drugs Standard Control Organisation (CDSCO) to market palivizumab, a preventive therapy for RSV. This injection is available as palivizumab 100 mg/ml in single-dose vials of 50 mg/0.5 ml and 100 mg/ml for intramuscular administration. Palivizumab is indicated for infants born at ≤35 weeks gestation, children requiring treatment for bronchopulmonary dysplasia (BPD), and those with hemodynamically significant congenital heart disease (CHD). This approval represents the first preventive therapy for RSV available in India.

Regional Insights

North America was the largest region in the synagis market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Synagis Market?

The synagis market consists of sales of pre-filled, single-dose vials and injectable solutions. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Synagis Market Report 2026?

The synagis market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the synagis industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.